Sammi Dali, MD
Interventional Cardiology · Michigan City, INNPI 1407825722
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 21.0%.
Across 463 payments — averaging $35.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$3K
- Medtronic$2K
- Terumo Medical Corporation$2K
- Abbott$2K
- Johnson & Johnson$989
- Medical Device Business Services, Inc.$790
- plus $6K from 31 others
What the payments were for
- Travel & lodging$7,68346%
- Food & beverage$8,75753%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 19 | $3,497 |
| Medtronic | 20 | $2,305 |
| Terumo Medical Corporation | 11 | $1,748 |
| Abbott | 15 | $1,542 |
| Johnson & Johnson | 84 | $989 |
| Medical Device Business Services, Inc. | 32 | $790 |
| Novartis | 49 | $743 |
| AstraZeneca | 27 | $499 |
| Boston Scientific | 9 | $497 |
| Amgen | 20 | $474 |
| Esperion Therapeutics, Inc. | 39 | $422 |
| Cook Medical LLC | 12 | $315 |
| E.r. Squibb & Sons, L.L.C. | 8 | $304 |
| Boehringer Ingelheim | 17 | $297 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $252 |
| Pfizer | 11 | $215 |
| Vifor Pharma, Inc. | 10 | $209 |
| Alnylam Pharmaceuticals Inc. | 8 | $195 |
| Edwards Lifesciences | 3 | $168 |
| Kowa Pharmaceuticals America, Inc. | 20 | $168 |
| Abiomed | 1 | $147 |
| Penumbra, Inc. | 1 | $144 |
| Teleflex LLC | 2 | $115 |
| Merck | 8 | $112 |
| Chiesi USA, Inc. | 3 | $100 |
| Actelion Pharmaceuticals US, Inc. | 5 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Cardiovascular Systems Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $35 |
| Amryt Pharma Holdings Ltd | 2 | $30 |
| Gilead | 2 | $26 |
| United Therapeutics Corporation | 1 | $22 |
| Angiodynamics, Inc. | 1 | $16 |
| Bayer | 1 | $14 |
| Shockwave Medical, Inc | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLIDESHEATH SLENDER$1,673
- COREVALVE EVOLUT R$1,568
- EXCLUDER AAA Endoprosthesis$1,476
- GORE CARDIOFORM Septal Occluder$1,326
- NAVITOR$692
- Carto 3$486
- TAG Thoracic Endoprosthesis$322
- ENSITE$174
- AMPLATZER$168
- Impella$147
- Indigo System$144
- MitraClip$143
- GENERAL - STRUCTURAL HEART$128
- CAMZYOS$116
- Repatha$110
How this compares
$16,641 in reported general payments places this provider in the 75th percentile of 170 interventional cardiology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $61,533 |
| EntrestoSacubitril/Valsartan | 44 | $47,922 |
| BrilintaTicagrelor | 14 | $10,302 |
| Metoprolol Succinate | 133 | $1,735 |
| Ezetimibe | 34 | $797 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 25 | $669 |
| Valsartan | 13 | $571 |
| Losartan Potassium | 46 | $548 |
| ClopidogrelClopidogrel Bisulfate | 67 | $536 |
| Atorvastatin Calcium | 79 | $511 |
| SotalolSotalol Hcl | 15 | $413 |
| Amlodipine Besylate | 45 | $310 |
| Rosuvastatin Calcium | 44 | $296 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $279 |
| Carvedilol | 29 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $215 | $61,53364 claims |
| NovartisEntresto | $743 | $47,92244 claims |
| AstraZenecaBrilinta | $499 | $10,30214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 170 interventional cardiology providers in Indiana.
Other interventional cardiology in Michigan City
- Michael FlisakMichigan City$11K
- Samer AbbasEast Chicago$395K
- James HermillerIndianapolis$307K
- Woodrow CoreyIndianapolis$262K
- Muzammil MusaniFort Wayne$184K
- Dean FerreraEast Chicago$180K
- Shashidhar DivakaruniMunster$97K
- Jarrod FrizzellEvansville$86K
- Navneet LatherNoblesville$83K
- Michael BallIndianapolis$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.